AstraZeneca plc 19% Potential Decrease Indicated by HSBC

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc with EPIC/TICKER (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘REDUCE’ this morning by analysts at HSBC. AstraZeneca plc are listed in the Health Care sector within UK Main Market. HSBC have set a target price of 6690 GBX on its stock. This is indicating the analyst believes there is a potential downside of -19.0% from today’s opening price of 8262 GBX. Over the last 30 and 90 trading days the company share price has increased 1046 points and increased 767 points respectively. The 1 year high stock price is 8444.72 GBX while the 52 week low for the share price is 5626 GBX.

AstraZeneca plc has a 50 day moving average of 7,423.28 GBX and a 200 Day Moving Average share price is recorded at 7,422.35. There are currently 1,312,240,429 shares in issue with the average daily volume traded being 3,288,929. Market capitalisation for LON:AZN is £109,978,870,354 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
    AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.

      Search

      Search